Globus Medical Q4 2024 Earnings Report
Key Takeaways
Globus Medical achieved Q4 2024 revenue of $657.3 million, reflecting a 6.6% increase year-over-year. GAAP net income reached $26.5 million, while non-GAAP net income stood at $117.4 million. Non-GAAP diluted EPS was $0.84, marking a 35.7% improvement from Q4 2023. The company's U.S. sales grew by 6.3%, while international sales increased by 7.7%.
Q4 2024 revenue increased by 6.6% year-over-year to $657.3 million.
GAAP net income surged 76.3% to $26.5 million.
Non-GAAP diluted EPS rose 35.7% to $0.84.
International revenue growth outpaced U.S. sales with an 8.9% increase on a constant currency basis.
Globus Medical Revenue
Globus Medical EPS
Globus Medical Revenue by Segment
Globus Medical Revenue by Geographic Location
Forward Guidance
Globus Medical reaffirms its 2025 revenue guidance of $2.66B to $2.69B, with expected non-GAAP EPS between $3.40 and $3.50. Following the anticipated Nevro acquisition, full-year revenue is projected to reach $2.80B to $2.90B, with non-GAAP EPS of $3.10 to $3.40.
Positive Outlook
- Expected revenue growth to $2.66B-$2.69B in 2025.
- Non-GAAP EPS guidance set between $3.40-$3.50.
- Further revenue increase expected post-Nevro acquisition.
- Continued operational efficiencies and cost management focus.
- Ongoing investment in innovation and spine technology solutions.
Challenges Ahead
- Potential integration challenges with Nevro acquisition.
- Foreign currency fluctuations may impact financial results.
- Increased competition in the musculoskeletal technology market.
- Macroeconomic uncertainties could affect demand.
- Regulatory risks associated with product approvals and compliance.
Revenue & Expenses
Visualization of income flow from segment revenue to net income